Contributions
Abstract: EP1665
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Introduction: Dimethyl Fumarate (DMF) was FDA-approved for treatment of Multiple Sclerosis (MS) in March 2013. At Ochsner Health System (OHS), we have observed an increased incidence of pulmonary embolism (PE) in patients on DMF.
Objectives: To explore whether DMF use is associated with an increased risk of PE.
Aims: To calculate the cumulative incidence of PE in MS patients taking DMF at OHS between 5/2013-5/2018, and compare it to the cumulative incidence of PE in MS patients not taking DMF at OHS System between 5/2013-5/2018.
Methods: We conducted a retrospective chart review of MS patients between the ages of 18 and 55 treated at OHS between May 2013 and May 2018. All data were collected from Ochsner's electronic health record (Epic). Within this cohort, we determined the cumulative incidence of PE in patients taking DMF and the cumulative incidence of PE in patients not on DMF.
Results: A total of 1,614 patients with MS aged 18-55 were treated at OHS between 5/2013 and 5/2018. Within this group, 424 patients were treated with DMF and 1,190 patients were not treated with DMF. There were 5 PE events (cumulative incidence 1.2%) within the DMF group, and 3 PE events (cumulative incidence 0.25%) within the no DMF group. The difference in the cumulated incidence of PE in MS patients on DMF as compared to MS patients not on DMF is statistically significant at p = 0.03 (Fisher exact test).
Conclusions: DMF may increase the risk of PE in patients with MS.
Disclosure: Gracy Juba: nothing to disclose
Bridget Bagert: nothing to disclose
Abstract: EP1665
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Introduction: Dimethyl Fumarate (DMF) was FDA-approved for treatment of Multiple Sclerosis (MS) in March 2013. At Ochsner Health System (OHS), we have observed an increased incidence of pulmonary embolism (PE) in patients on DMF.
Objectives: To explore whether DMF use is associated with an increased risk of PE.
Aims: To calculate the cumulative incidence of PE in MS patients taking DMF at OHS between 5/2013-5/2018, and compare it to the cumulative incidence of PE in MS patients not taking DMF at OHS System between 5/2013-5/2018.
Methods: We conducted a retrospective chart review of MS patients between the ages of 18 and 55 treated at OHS between May 2013 and May 2018. All data were collected from Ochsner's electronic health record (Epic). Within this cohort, we determined the cumulative incidence of PE in patients taking DMF and the cumulative incidence of PE in patients not on DMF.
Results: A total of 1,614 patients with MS aged 18-55 were treated at OHS between 5/2013 and 5/2018. Within this group, 424 patients were treated with DMF and 1,190 patients were not treated with DMF. There were 5 PE events (cumulative incidence 1.2%) within the DMF group, and 3 PE events (cumulative incidence 0.25%) within the no DMF group. The difference in the cumulated incidence of PE in MS patients on DMF as compared to MS patients not on DMF is statistically significant at p = 0.03 (Fisher exact test).
Conclusions: DMF may increase the risk of PE in patients with MS.
Disclosure: Gracy Juba: nothing to disclose
Bridget Bagert: nothing to disclose